STEAP2 recombinant proteins and antibodies

Six Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2) is a six-transmembrane protein and a member of the STEAP family, initially identified in prostate tissue. It is localized on the plasma membrane and endosomal compartments, functioning in metal ion transport and reduction, particularly for iron and copper. While STEAP2 expression is limited in normal tissues, it is markedly overexpressed in various cancers—most notably prostate, bladder, renal, colorectal, and breast cancers—and is associated with tumor aggressiveness, invasiveness, and metastatic potential. These characteristics make STEAP2 an attractive biomarker and therapeutic target for cancer diagnosis and treatment.

In drug development, STEAP2 has gained attention as a promising target for monoclonal antibodies, ADCs (antibody–drug conjugates), cancer vaccines, and T cell-based therapies due to its membrane localization and tumor-specific expression. Current research focuses primarily on prostate cancer immunotherapy. Companies such as ImmunoPrecise Antibodies and Genmab are developing STEAP2-targeting monoclonal and bispecific antibodies, while Astellas Pharma and Johnson & Johnson have included STEAP2 in their prostate cancer target pipelines for CAR-T and ADC programs. Meanwhile, academic studies continue to investigate the role of STEAP2 in tumor iron metabolism and immune evasion, further broadening its therapeutic potential across multiple cancer types. Overall, STEAP2 is emerging as a promising immuno-oncology target, particularly for prostate and solid tumors. With advances in antibody engineering and cell therapy platforms, STEAP2 is expected to play a significant role in next-generation precision cancer treatments.

To assist in the development of STEAP2 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting STEAP2, including STEAP2 recombinant proteins, STEAP2 full-length membrane proteins, anti-STEAP2 monoclonal antibodies and Biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting STEAP2, which can screen out the lead antibody molecules required by customers in just 20 days. For more details, please contact us.